{"prompt": "['2014-0546', 'August 7, 2017', 'Page 12 of 49', 'Final study results are pending.', '1.3.', 'Summary of Potential Risks', \"The Reference Safety Information for this study is in the latest Rigosertib's IB A summary of\", 'expected drug-related treatment-emergent adverse events (AEs) in studies of oral rigosertib is', 'presented below (Table 1).']['2014-0546', 'August 7, 2017', 'Page 13 of 49', 'Table 1', 'Reference Safety Information (RSI)', 'Summary of Expected Drug-related Treatment-emergent Adverse Events by Preferred Term, Sorted by Frequency, in Studies of Oral Rigosertib', 'Safety-Evaluable (N=337)', 'Rigosertib Integrated Analysis', 'MedDRA Preferred Term [1][2]', 'Any Grade', 'Grade 1', 'Grade 2', 'Grade 3', 'Grade 4', 'Grade 5', 'Dysuria', '103 (30.6%)', '35 (10.4%)', '61 (18.1%)', '7 (2.1%)', '0', '0', 'Pollakiuria', '67 (19.9%)', '25 (7.4%)', '42 (12.5%)', '0', '0', '0', 'Haematuria', '62 (18.4%)', '27 (8.0%)', '25 (7.4%)', '10 (3.0%)', '0', '0', 'Micturition urgency', '43 (12.8%)', '20 (5.9%)', '22 (6.5%)', '1 (0.3%)', '0', '0', 'Fatigue', '40 (11.9%)', '18 (5.3%)', '19 (5.6%)', '3 (0.9%)', '0', '0', 'Nausea', '39 (11.6%)', '27 (8.0%)', '9 (2.7%)', '3 (0.9%)', '0', '0', 'Urinary tract pain', '31 (9.2%)', '11 (3.3%)', '18 (5.3%)', '2 (0.6%)', '0', '0', 'Diarrhoea', '28 (8.3%)', '19 (5.6%)', '8 (2.4%)', '1 (0.3%)', '0', '0', 'Urinary tract infection', '27 (8.0%)', '3 (0.9%)', '21 (6.2%)', '3 (0.9%)', '0', '0', 'Decreased appetite', '18 (5.3%)', '15 (4.5%)', '2 (0.6%)', '1 (0.3%)', '0', '0', 'Cystitis', '17 (5.0%)', '2 (0.6%)', '8 (2.4%)', '7 (2.1%)', '0', '0', 'Constipation', '13 (3.9%)', '11 (3.3%)', '2 (0.6%)', '0', '0', '0', 'Neutropenia', '10 (3.0%)', '0', '1 (0.3%)', '1 (0.3%)', '8 (2.4%)', '0', 'Vomiting', '10 (3.0%)', '8 (2.4%)', '1 (0.3%)', '1 (0.3%)', '0', '0', 'Nocturia', '9 (2.7%)', '3 (0.9%)', '6 (1.8%)', '0', '0', '0', 'Abdominal pain', '8 (2.4%)', '7 (2.1%)', '1 (0.3%)', '0', '0', '0', 'Hyponatraemia', '8 (2.4%)', '4 (1.2%)', '0', '4 (1.2%)', '0', '0', 'Proteinuria', '8 (2.4%)', '2 (0.6%)', '4 (1.2%)', '2 (0.6%)', '0', '0', 'Thrombocytopenia', '8 (2.4%)', '1 (0.3%)', '0', '2 (0.6%)', '5 (1.5%)', '0', 'Dyspepsia', '7 (2.1%)', '6 (1.8%)', '1 (0.3%)', '0', '0', '0', 'Headache', '7 (2.1%)', '5 (1.5%)', '2 (0.6%)', '0', '0', '0', 'Urinary incontinence', '7 (2.1%)', '0', '7 (2.1%)', '0', '0', '0', 'Neutrophil count decreased', '6 (1.8%)', '0', '0', '0', '6 (1.8%)', '0']['2014-0546', 'August 7, 2017', 'Page 14 of 49', 'Table 1', 'Reference Safety Information (RSI)', 'Summary of Expected Drug-related Treatment-emergent Adverse Events by Preferred Term, Sorted by Frequency, in Studies of Oral Rigosertib', 'Safety-Evaluable (N=337)', 'Rigosertib Integrated Analysis', 'MedDRA Preferred Term [1][2]', 'Any Grade', 'Grade 1', 'Grade 2', 'Grade 3', 'Grade 4', 'Grade 5', 'Abdominal discomfort', '5 (1.5%)', '3 (0.9%)', '2 (0.6%)', '0', '0', '0', 'Anaemia', '5 (1.5%)', '3 (0.9%)', '0', '2 (0.6%)', '0', '0', 'Cystitis noninfective', '5 (1.5%)', '3 (0.9%)', '2 (0.6%)', '0', '0', '0', 'Dysgeusia', '5 (1.5%)', '5 (1.5%)', '0', '0', '0', '0', 'Aspartate aminotransferase increased', '4 (1.2%)', '4 (1.2%)', '0', '0', '0', '0', 'Chromaturia', '4 (1.2%)', '4 (1.2%)', '0', '0', '0', '0', 'Flatulence', '4 (1.2%)', '4 (1.2%)', '0', '0', '0', '0', 'Abdominal distension', '3 (0.9%)', '2 (0.6%)', '1 (0.3%)', '0', '0', '0', 'Abdominal pain upper', '3 (0.9%)', '1 (0.3%)', '2 (0.6%)', '0', '0', '0', 'Alanine aminotransferase increased', '3 (0.9%)', '1 (0.3%)', '2 (0.6%)', '0', '0', '0', 'Blood bilirubin increased', '3 (0.9%)', '3 (0.9%)', '0', '0', '0', '0', 'Platelet count decreased', '3 (0.9%)', '0', '0', '1 (0.3%)', '2 (0.6%)', '0', 'Urinary hesitation', '3 (0.9%)', '0', '3 (0.9%)', '0', '0', '0', 'Urinary retention', '3 (0.9%)', '3 (0.9%)', '0', '0', '0', '0', 'Bladder irritation', '2 (0.6%)', '1 (0.3%)', '1 (0.3%)', '0', '0', '0', 'Bladder spasm', '2 (0.6%)', '2 (0.6%)', '0', '0', '0', '0', 'Blood urine present', '2 (0.6%)', '1 (0.3%)', '1 (0.3%)', '0', '0', '0', 'Confusional state', '2 (0.6%)', '1 (0.3%)', '1 (0.3%)', '0', '0', '0', 'Frequent bowel movements', '2 (0.6%)', '2 (0.6%)', '0', '0', '0', '0', 'Leukopenia', '2 (0.6%)', '0', '0', '1 (0.3%)', '1 (0.3%)', '0', 'Lymphocyte count decreased', '2 (0.6%)', '2 (0.6%)', '0', '0', '0', '0', 'Malaise', '2 (0.6%)', '1 (0.3%)', '1 (0.3%)', '0', '0', '0', 'White blood cell count decreased', '2 (0.6%)', '1 (0.3%)', '0', '1 (0.3%)', '0', '0', 'Bladder pain', '1 (0.3%)', '0', '1 (0.3%)', '0', '0', '0']\n\n###\n\n", "completion": "END"}